Sage Journals: Discover world-class research

Abstract

Background and objective:

Currently, there is no effective therapy available for liver fibrosis. This study aims to evaluate the efficacy of renin angiotensin system inhibitors on liver fibrosis.

Method:

Full-text randomized controlled trials in patients with liver fibrosis were identified and included in the meta-analysis. The primary outcome measure was the histological fibrosis score of the liver. Secondary outcome measures included fibrosis area of the liver, serological levels of fibrosis markers, adverse events, and withdrawals.

Results:

From 6973 non-duplicated entries by systematic search, four randomized controlled trials with 210 patients were identified. The renin angiotensin system inhibitors therapy resulted in a marginally significant reduction in liver fibrosis score (MD = -0.30; 95% CI: -0.62–0.02, p = 0.05) and a significant reduction in liver fibrosis area (MD = -2.36%; 95% CI: -4.22%–-0.50%, p = 0.01) as compared with control. The therapy was well tolerated and there was no significant difference in withdrawals between treatment and control groups (RD = 0.00; 95% CI: -0.06–0.06, p = 0.97).

Conclusions:

Renin angiotensin system inhibitor therapy results in a reduction in liver fibrosis score and liver fibrosis area in patients with hepatic fibrosis with good safety profile. However, randomized controlled trials of high-quality will clarify the effectiveness of renin angiotensin system inhibitors on liver fibrosis.

Keywords

Angiotensin-converting-enzyme inhibitors angiotensin receptor blocker liver fibrosis treatment

Introduction

Chronic liver diseases, including chronic viral hepatitis, non-alcoholic fatty liver disease, chronic alcoholic liver disease and others, if untreated, are generally characterized by progressive inflammation and liver fibrosis, which may lead to liver cirrhosis and hepatocellular carcinoma (HCC).^1–3 The efficacy of current therapies for liver diseases is limited and there are no effective therapies currently available for liver fibrosis.

Liver fibrosis is characterized by the excess production and deposition of extracellular matrix (ECM). A major source of ECM includes hepatic satellite cells (HSCs).⁴ HSCs are stimulated by fibrogenic cytokines, one of which is angiotensin II,⁵ an effector hormone of the renin angiotensin system (RAS). The profibrogenic effect of angiotensin II is associated with an increased concentration of transforming growth factor β1 (TGF-β1).⁶ Previous research has showed that angiotensin II increased the TGF-β1 mRNA expression in the activated HSCs, and this effect was completely blocked by one of the RAS inhibitors, angiotensin II receptor blocker (ARB) candesartan.⁷ RAS inhibition causes a decrease in connective tissue growth factor and angiotensin II type-1 (AT1) receptor expression, and is associated with decreased TGF-β1 expression in the injured liver.^8,9 In vitro experiments demonstrated that telmisartan, another ARB, and AT1 receptor knockdown following exposure of long chain fatty acids reduced cellular lipid accumulation,¹⁰ suggesting that AT1 receptor and its blocker may play a key biological role in the regulation of hepatic lipid metabolism.¹⁰ In another study, RAS was suggested to be involved in the transition of steatosis to steatohepatitis.¹¹ Steatosis has been shown to be associated with fibrosis severity in chronic hepatitis caused by HBV or HCV infection¹² and non-alcoholic fatty liver disease.¹³ Angiotensin II induces contraction and proliferation of HSCs by activating AT1 receptors, which are considered principal effectors of hepatic fibrosis.¹⁴ Studies in various animal models with liver fibrosis showed that angiotensin-converting-enzyme inhibitors (ACEIs)/ARBs may play an important role in anti-liver fibrosis.^15–20 ACEIs are key negative regulators of the RAS, and function to limit fibrosis through the degradation of angiotensin II, and administration of recombinant ACEIs showed therapeutic potential in liver fibrosis.²¹ The ARB losartan was also shown to significantly inhibit the progression of liver fibrosis in a hepatic fibrosis rat model.²²

In humans, many studies have shown the role of RAS in liver diseases. One study found that the circulating RAS components, such as plasma renin and angiotensin II, were markedly elevated in patients with advanced liver disease as compared with healthy controls.²³ Another study demonstrated that elevated circulating angiotensin-converting enzyme (ACE) level may be used as a marker of fibrosis in patients with chronic hepatitis B.²⁴ A recent study also showed that serum ACE levels may offer an easy, accurate and inexpensive noninvasive method for differentiating significant from nonsignificant liver fibrosis in autoimmune hepatitis.²⁵ Treatment with losartan resulted in a significant decrease in hepatic fibrosis marker, plasma TGF-β1.²⁶ Two retrospective studies found that hypertensive patients receiving ACEIs or ARBs had less fibrosis than hypertensive patients who did not receive these drugs.^27,28 A pilot study showed that losartan could improve the liver fibrosis stage.²⁹ Two prospective studies found that, in early stage cirrhosis and nonalcoholic steatohepatitis patients, ARBs could improve aminotransferases and decrease TGF-β1 levels.^26,30 However, the effectiveness of ACEIs/ARBs on liver fibrosis is conflicting. A 48-month follow-up revealed that single treatment with ACEI did not exert inhibitory effects on hepatic fibrosis.³¹ In a hepatitis C long-term treatment against cirrhosis trial, continuous ACEIs/ARBs use for 3.5 years did not retard the progression of hepatic fibrosis.³² Several randomized controlled trials (RCTs) investigated the role of ACEI/ARBs in liver fibrosis with conflicting findings.^23,28–30 The aim of this study was to conduct a systematic review in relation to the role of ACEI/ARBs in the treatment of liver fibrosis and a meta-analysis of RCTs assessing the efficacy and safety of using ACEI/ARBs for liver fibrosis.

Methods

Search strategy

Eligible trials were identified up to 30 April 2014 through electronic searches of The Cochrane Library, PubMed, Medline (Ovid), Web of Knowledge, Elsevier (ScienceDirect OnLine, SDOL), SpringerLink, and Wiley InterScience. The references of identified trials were hand-searched. Search terms were: “renin angiotensin aldosterone system”, “renin angiotensin system”, “angiotensin converting enzyme inhibitors”, “angiotensin receptor blockers”, “RAAS”, “RAS”, “ACEI”, “ARB”, and “liver fibrosis” and “hepatic fibrosis”.

Inclusion and exclusion criteria

Inclusion and exclusion criteria were determined by two researchers (QZ and NL). Studies were considered to be included in this review if they met the following inclusion criteria: (i) English language; (ii) describing a pharmacological intervention for liver fibrosis or hepatic fibrosis; (iii) using ACEIs/ARBs therapy; (iv) liver fibrosis score and area or blood liver fibrosis marker undertaken at baseline and study end; (v) the participants without infection with HIV. The RCT would be considered to be included in meta-analysis. All other studies not meeting the inclusion criteria were excluded.

Data extraction and outcome measures

Data were extracted independently by two reviewers (QZ and NL) and validated by a third reviewer (ZL). The following data were extracted: primary author, year, and study design, numbers of patients randomized and lost during follow-up, and dosage and duration of intervention.

The primary outcome measure was histological fibrosis score of the liver. Secondary outcome measures included fibrosis area of the liver, serological levels of fibrosis markers, adverse events, and withdrawals.

Methodological quality score of the included studies

The quality of the RCTs was assessed by the Jadad score system.³³ The Jadad score system is the only known 5-item scale developed with standard scale development techniques and has been used to assess the quality of RCTs for almost two decades. It is a simple, short, and reliable approach. The Jadad scores would be higher and more consistent if quality assessment was blinded; the inadequate allocation concealment would exaggerate treatment efficacy in RCTs.^34,35 Therefore, the Jadad score system was used to assess the quality of the RCTs.

Data synthesis and statistical analysis

Continuous data were presented as mean difference (MD) with a 95% confidence interval (CI). Inter-study heterogeneity was assessed with χ² tests and the I² measure.³⁶ I² value < 25% was regarded as no heterogeneity. Meta-analysis was performed in Review Manager 5 (The Cochrane Collaboration, Oxford, England). Random effects model was used when a significant heterogeneity exists among the studies analyzed. Adverse events and withdrawals were reported as a risk difference (RD, 95% CI).

Results

Search

A total of 6973 non-duplicated entries were identified by the systematic search, and titles were reviewed. Abstracts and full texts were obtained for articles to determine eligibility for inclusion. Fifteen papers were included in this review^{27–32,37–45} (Table 1) and four RCTs^30,40,43,44 (Table 2) were identified and included in the meta-analysis (Figure 1). The reasons for excluding the 11 studies from meta-analysis are listed in Table 3.

Table 1.

Patient characteristics of the review.

First author, year	Participants		Duration	Liver biopsies	Noninvasive fibrosis markers	The effects of Angiotensin blockade on fibrosis
Terui Y, 2002³⁰	30 patients with early stages of chronic hepatitis C	RCT	Not mentioned	Yes	Yes	Promising beneficial effects
Rimola A, 2004²⁷	128 recurrent hepatitis C after LT	Retrospective cohort study	41 months (median)	Yes	No	Beneficial effects
Rincon D, 2005³⁷	123 HCV-patients who received LT	Retrospective cohort study	> 6 months	Yes	No	No beneficial effects
Sookoian S, 2005²⁹	23 patients with chronic hepatitis C non-responders	Prospective cohort study	14 months	Yes	No	Beneficial effects
Yoshiji H, 2005³⁸	20 patients with chronic hepatitis C	RCT	12 months	No	Yes	Promising beneficial effects
Yoshiji H, 2006³⁹	40 patients with chronic hepatitis C	RCT	12 months	No	Yes	Beneficial effects
Debernardi-Venon W, 2007⁴⁰	47 selected cirrhotic patients	RCT	12 months	No	Yes	Promising beneficial effects
Corey KE, 2009²⁸	234 patients with hepatitis C	Retrospective cohort study	5.08 years	Yes	No	Beneficial effects
Colmenero J, 2009⁴¹	14 patients with CHC with liver fibrosis	Uncontrolled open-label study	18 months	Yes	No	Promising beneficial effects
Cholongitas E, 2010⁴²	102 recurrent hepatitis C after LT	Retrospective cohort study	13 months (median)	Yes	No	No beneficial effects
Abu Dayyeh BK, 2011³²	192 patients with hepatitis C	RCT	42 months	Yes	No	No beneficial effects
Hidaka H, 2011⁴³	48 selected cirrhotic patients	RCT	12 months	No	Yes	Promising beneficial effects
Kim MY, 2012⁴⁴	85 patients with compensated alcoholic liver fibrosis	RCT	6 months	Yes	No	Promising beneficial effects
Yoshiji H, 2012³¹	110 patients with cirrhosis associated with hepatocellular carcinoma	RCT	48 months	No	Yes	Beneficial effects
Guillaud O, 2013⁴⁵	109 recurrent hepatitis C after LT	Retrospective cohort study	23 months (median)	Yes	No	No beneficial effects

RCT, randomized controlled trial; LT, liver transplantation.

Table 2.

Characteristics and quality analysis of studies included in the meta-analysis.

Author, year	No. of patients (total)	Etiology of liver fibrosis	Pharmacological intervention	Control	Duration	Design	Jadad score
Terui Y, 2002³⁰	30	30 viral liver disease	Losartan 50 mg/d plus UDCA 600 mg/d	UDCA 600 mg/d	N/A	RCT	2
Debernardi-Venon W, 2007⁴⁰	47	40 viral and 7 alcohol liver disease	Candesartan 8mg/d	No treatment	12 mo	RCT	5
Hidaka H, 2011⁴³	48	31 viral, 9 alcohol liver disease and 8 others	Olmesartan 10–40 mg/d (10 to 20 then to 40 mg)	No treatment	12 mo	RCT	5
Kim MY, 2012⁴⁴	85	85 alcohol liver disease	Candesartan 8mg/d plus UDCA 600mg/d	UDCA 600 mg/d	6 mo	RCT	5

N/A, data not available; UDCA, ursodeoxycholic acid.

Figure 1.

Flowchart showing the process of literature searching and selection.

Table 3.

Details of exclusion reasons.

First author, year	The exclusion reasons
Rimola A, 2004²⁷	Not RCT. The results were demonstrated by percentage of cirrhosis or mean and range of cirrhosis but not mean ± SD which could not be calculated with other studies in the meta-analysis.
Rincon D, 2005³⁷	Not RCT. The results were demonstrated by percentage of fibrosis stage 2–4 but not mean ± SD which could not be calculated with other studies in the meta-analysis.
Sookoian S, 2005²⁹	Not RCT. The basic fibrosis was not comparable between the two groups.
Yoshiji H, 2005³⁸	The treated group was given both IFN and perindopril while the controlled group treated nothing.
Yoshiji H, 2006³⁹	The results were demonstrated by changed percentage of fibrosis score which could not be calculated with other studies in the meta-analysis.
Corey KE, 2009²⁸	Not RCT. The results were demonstrated by mean of cirrhosis without SD which could not be calculated with other studies in the meta-analysis.
Colmenero J, 2009⁴¹	Not RCT. No control group.
Cholongitas E, 2010⁴²	Not RCT. The results were demonstrated by changed mean fibrosis score but not mean ± SD which could not be calculated with other studies in the meta-analysis.
Abu Dayyeh BK, 2011³²	The results were demonstrated by percentage of 2-point increases in fibrosis which could not be calculated with other studies in the meta-analysis.
Yoshiji H, 2012³¹	The treated group was given both IFN and perindopril while the controlled group treated nothing.
Guillaud O, 2013⁴⁵	Not RCT. The results were demonstrated by change of median fibrosis score which could not be calculated with other studies in the meta-analysis.

RCT, randomized controlled trial; SD, standard deviation; IFN, interferon.

Patient characteristics

Two hundred and ten patients, including 148 male and 62 female, with liver fibrosis of various etiologies, participating in the four studies met the inclusion criteria. The mean age was 55.5 (18–75) years. Of the 210 patients, the etiologies of liver fibrosis were: 101 alcoholic, 101 viral and 8 other causes.

Interventions

For the intervention, all the studies used ARBs: one study used olmesartan for treatment and no treatment as control,⁴³ one used candesartan for treatment and no treatment as control,⁴⁰ one used losartan plus ursodeoxycholic acid (UDCA) for treatment and UDCA as control,³⁰ and one used candesartan plus UDCA for treatment and UDCA as control.⁴⁴ Details of treatment and control medication and duration are shown in Table 2.

Fibrosis score of the liver

Two of the four studies underwent liver biopsy before study entry and at the end of the study and provided sufficient data for the calculation of mean differences and 95% CI of histological fibrosis score evaluated according to the METAVIR scoring system.^30,44 The ARB therapy showed an insignificant but marginally positive effect on fibrosis score (MD = -0.30, 95% CI: -0.62–0.02, P = 0.05; Figure 2). No significant heterogeneity between these studies was observed (I² = 0%, P = 1.00; Figure 2).

Figure 2.

Meta-analysis of fibrosis score of the liver in angiotensin receptor blockers treatment and control patients.

Fibrosis area of the liver

Two of the four studies provided sufficient data for the calculation of mean differences and 95% CI of fibrosis area of the liver (%),^30,44 which was expressed as the percentage of the total area measured using an image analysis system.^30,44 The ARB therapy resulted in a significant reduction in fibrosis area in comparison with control (MD = -2.36, 95% CI: -4.22–-0.50, P = 0.01; Figure 3). There was a modest heterogeneity among these studies (I² = 52%, P = 0.15; Figure 3).

Figure 3.

Meta-analysis of fibrosis area of the liver in angiotensin receptor blockers treatment and control patients.

Fibrosis markers of the liver

The serological levels of fibrosis markers assessed with sufficient data for the calculation of mean differences and 95% CI were type IV collagen in two studies^30,43 and TGF-β1 in three studies.^30,40,43 ARB therapy was not associated with decreased levels of type IV collagen as compared with control (MD = -0.64, 95% CI: -1.63–0.36, P = 0.21). There was a modest heterogeneity between the studies (I² = 51%, P = 0.15). The ARB therapy was not significantly associated with reduction in TGF-β1 levels as compared with control (MD = -3.71, 95% CI: -9.39–1.97, P = 0.20; Figure 4). A significant heterogeneity existed among the studies (I² = 77%, P = 0.01; Figure 4).

Figure 4.

Meta-analysis of fibrosis markers (serological levels of transforming growth factor beta 1 (TGF-β1)) in angiotensin receptor blockers treatment and control patients.

Adverse events and withdrawals

ARBs were well tolerated by all patients in all of the studies,^30,40,43,44 except one patient in one study did not complete the study because of symptomatic hypotension.⁴³ Overall, there was no significant difference in withdrawals in the treatment and control groups (RD = 0.00; 95% CI -0.06–0.06, P = 0.97). Details regarding adverse events and withdrawals are provided in Table 4.

Table 4.

Adverse events and withdrawals of studies included in meta-analyses.

Author, year	Intervention group	Control group
Terui Y, 2002³⁰	No adverse events or withdrawals	No adverse events or withdrawals
Debernardi-Venon W, 2007⁴⁰	No adverse events or withdrawals	No adverse events or withdrawals
Hidaka H, 2011⁴³	2 withdrawals (1 for symptomatic hypotension, 1 for patient choice)	1 withdrawal (patient choice)
Kim MY, 2012⁴⁴	5 withdrawals (2 for ingestion of alcohol, 1 for low medical compliance, 2 loss to follow-up)	7 withdrawals (3 for ingestion of alcohol, 2 for low medical compliance, 2 loss to follow-up)

Methodological quality of the included studies

The quality assessment for each study is shown in Table 2. No study was double-blinded. No study had > 5% loss to follow-up.

Discussion

In many animal models for liver fibrosis, ACEI/ARBs could retard the progression of liver fibrosis and/or decrease the serum TGF-β1.^{15,17,46–49} In human retrospective studies, ACEI/ARBs could decrease liver fibrosis in patients with chronic liver disease.^27,28 In patients with recurrent hepatitis C virus infection after liver transplantation, the fibrosis stage and the fibrosis progression index in the liver biopsy obtained at the end of follow-up was significantly lower in patients who were treated with ACEI/ARBs than in those without the use of ACEI/ARBs.²⁷ However, the findings pertinent to the effect of ACEI/ARBs on hepatic fibrosis are still conflicting. For example, in the studies of disease with the same etiology, a pilot study showed that losartan improved liver fibrosis stage in patients with chronic hepatitis C,²⁹ but continuous ACEI/ARB use for 3.5 years in a hepatitis C long-term treatment against cirrhosis cohort was not shown to retard the progression of hepatic fibrosis.³² Of note, these studies are mainly retrospective or pilot, which may limit the validity of the studies and partly contribute to the inconsistencies.

The present study provides the first meta-analysis of RCTs investigating the effect of ARBs on the liver fibrosis in humans. Despite heterogeneity among the studies, the analyses show that ARB therapy was marginally associated with the improvement in histological liver score and significantly associated with the improvement in fibrosis area of the liver. The therapy was well tolerated by patients and there were no significant withdrawals.

Hepatic histopathology remains the gold standard of liver fibrosis. Two studies in our analysis evaluated histological fibrosis score of the liver.^30,44 Our analysis showed that ARB therapy has a trend of positive effect on liver fibrosis assessed by METAVIR system. These two studies are well-designed RCTs with no significant heterogeneity. This may confer more authenticity on the results. One study also evaluated liver fibrosis using Laennec fibrosis scoring system which divided cirrhosis into three subclasses and was believed to have a more detailed estimation of fibrosis,^30,44 showing that, although no significance in fibrosis according to the METAVIR system, candesartan therapy significantly increased the improvement rate in fibrosis according to the Laennec system evaluated by either intention-to-treat (ITT) (33.3% vs. 11.6%, P = 0.020) or per-protocol (PP) analysis (37.8% vs. 13.9%, P = 0.032).^30,44 As the modification of METAVIR scoring system, the Laennec scoring system subdivides the liver cirrhosis stage F4 according to METAVIR scoring system into three (4A, 4B, 4C) stages based on ﬁbrosis thickness and nodule size. Studies showed that Laennec scoring system had a significant correlation to the clinical stages of cirrhosis, Child-Pugh and MELD scores, severity of portal hypertension, and the Laennec scoring system might have the potential in predicting the liver-related events because of the sub-classiﬁcation of cirrhosis.^50–52

The present analysis also shows that ARB therapy has a significant positive effect on liver fibrosis assessed by the fibrosis area of the liver. With regard to serological fibrosis markers, ARB therapy has no significant effect on type IV collagen and TGF-β1. ARB therapy has a significant positive effect on levels of hyaluronic acid (HA) in two studies^40,43 although pooled analysis was not performed because of the different measurements of this parameter in the studies.^40,43 Serum HA measurement is indicated to be a sensitive, specific and reliable marker for assessing the degree of liver fibrosis in chronic liver diseases^53–59 and monitoring the progressiveness of liver fibrosis and the histological response of hepatic fibrosis to treatment.^53,60 Comparatively, the serum levels of HA were suggested to be correlated with the degree of hepatic fibrosis more closely and specifically than type IV collagen.^60,61 The level of plasma TGF-β1 was not suggested to be a sensitive variable for the evaluation of hepatic fibrosis in both adult and child patients with chronic liver disease.^62–64 Furthermore, it should be noted that a well-designed study included in our analysis assessed the relative expression of TGF-β1 in liver tissue by real-time reverse transcriptase–polymerase chain reaction, showing a significant decrease of the relative expression of TGF-β1 in liver tissue in the candesartan group.⁴⁴ Collectively, it appears that ARB therapy is beneficial for the improvement of liver fibrosis, especially when evaluated by more sensitive, specific, and accurate measures such as Laennec fibrosis scoring system and serum HA level.

In all of the studies included in our analysis, the RAS inhibitors used were ARBs. Whether there are some distinctions between ARBs and ACEIs remains unclear. ARBs were shown to be superior to ACEIs in the suppression of hepatic fibrosis in an animal study.⁶⁵ Another study, however, showed that ARBs improved only the necroinflammation in paired biopsies but not the fibrosis progression in human.⁴² Methodologically, all of the studies included in our analysis are RCTs, but only patients in two studies underwent liver biopsy.^30,44 Moreover, though the random effects model was used in our analysis when there was significant heterogeneity among the studies, this may still lead to bias and decrease the authenticity and reliability of the analysis. Therefore, more prospective randomized controlled trials, including studies focusing on ACEIs and ARBs to distinguish their possible difference on liver fibrosis, are deserved to elucidate the role of RAS inhibitors in treating liver fibrosis.

In conclusion, this study shows that ARB therapy was associated with a trend in the improvement of histological liver fibrosis score and a significant improvement in fibrosis area of the liver in patients with liver fibrosis. More RCTs of high-quality using more precise evaluation parameters are needed to clarify the effectiveness of ACEI/ARBs on hepatic fibrosis in human liver disease.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Natural Science Foundation of China (Grant no. 81371798). We thank Dr Patrick C. Kellish from the Department of Anatomy and Cell Biology, University of Florida College of Medicine for the careful and expert editing of this paper.

References

Matsuzaki

Murata

Yoshida

. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007; 46: 48–57.

Sun

Karin

Obesity, inflammation, and liver cancer. J Hepatol 2012; 56: 704–713.

Berasain

Castillo

Perugorria

. Inflammation and liver cancer: New molecular links. Ann N Y Acad Sci 2009; 1155: 206–221.

Friedman

SL.

Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy. J Gastroenterol Hepatol 1999; 14: 618–633.

Bataller

Sancho-Bru

Gines

. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003; 125: 117–125.

Gaedeke

Peters

Noble

. Angiotensin II, TGF-beta and renal fibrosis. Contrib Nephrol 2001: 153–160.

Yoshiji

Kuriyama

Yoshii

. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34: 745–750.

Bataller

Sancho-Bru

Gines

. Liver fibrogenesis: A new role for the renin-angiotensin system. Antioxid Redox Signal 2005; 7: 1346–1355.

Kurikawa

Suga

Kuroda

. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol 2003; 139: 1085–1094.

10.

Nabeshima

Tazuma

Kanno

. Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol 2009; 50: 1226–1235.

11.

Vergniol

Barbu

Lemoine

. Progression of NAFLD in humans is associated with the activation of the renin-angiotensin system. J Hepatol 2011; 54: S348.

12.

Cacopardo

Camma

Petta

. Diagnostic and therapeutical role of vitamin D in chronic hepatitis C virus infection. Front Biosci (Elite Ed) 2012; 4: 1276–1286.

13.

Albano

Mottaran

Vidali

. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 2005; 54: 987–993.

14.

Bataller

Brenner

DA.

Liver fibrosis. J Clin Invest 2005; 115: 209–218.

15.

Meng

Yang

. Perindopril attenuates the progression of CCl4-inducing rat hepatic fibrosis. Chin J Hepatol 2004; 12: 32–34.

16.

Park

Baik

Choi

. Inhibitory effect of angiotensin blockade on hepatic fibrosis in common bile duct-ligated rats. Korean J Hepatol 2007; 13: 61–69.

17.

Toblli

Munoz

Cao

. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity 2008; 16: 770–776.

18.

Ohishi

Saito

Tsusaka

. Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. Hepatol Res 2001; 21: 147–158.

19.

Song

Huang

. Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats. J Gastroenterol Hepatol 2006; 21: 1250–1256.

20.

Martini

Alessandria

Debernardi Venon

. Angiotensin II type 1 receptor inhibition in early stage cirrhotic patients: Effects on portal pressure and liver fibrosis. J Hepatol 2004; 40: 70.

21.

Oesterreicher

Taura

De Minicis

. Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology 2009; 50: 929–938.

22.

Wei

. Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4). World J Gastroenterol 2000; 6: 540–545.

23.

Vilas-Boas

Ribeiro-Oliveira

Jr. Pereira

. Relationship between angiotensin-(1–7) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis. World J Gastroenterol 2009; 15: 2512–2519.

24.

Purnak

Beyazit

Oztas

. Serum angiotensin-converting enzyme level as a marker of fibrosis in patients with chronic hepatitis B. J Renin Angiotensin Aldosterone Syst 2012; 13: 244–249.

25.

Efe

Cengiz

Kahramanoglu-Aksoy

. Angiotensin-converting enzyme for noninvasive assessment of liver fibrosis in autoimmune hepatitis. Eur J Gastroenterol Hepatol 2015; 27: 649–654.

26.

Yokohama

Yoneda

Haneda

. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222–1225.

27.

Rimola

Londono

Guevara

. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004; 78: 686–691.

28.

Corey

Shah

Misdraji

. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int 2009; 29: 748–753.

29.

Sookoian

Fernandez

Castano

Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study. World J Gastroenterol 2005; 11: 7560–7563.

30.

Terui

Saito

Watanabe

. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 2002; 36: 1022.

31.

Yoshiji

Noguchi

Ikenaka

. Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosis. Mol Med Report 2012; 5: 539–544.

32.

Abu Dayyeh

Yang

Dienstag

. The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C trial cohort. Dig Dis Sci 2011; 56: 564–568.

33.

Jadad

Moore

Carroll

. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17: 1–12.

34.

Schulz

Chalmers

Hayes

. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408–412.

35.

Moher

Pham

Jones

. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609–613.

36.

Higgins

Thompson

SG.

Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–1558.

37.

Rincon

Nogales

Salcedo

. Influence of ace-inhibitors (ACEI) in the evolution of fibrosis after liver transplantation (LT) in HCV-patients. J Hepatol 2005; 42: 58.

38.

Yoshiji

Noguchi

Fukui

Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C. J Gastroenterol 2005; 40: 215–216.

39.

Yoshiji

Noguchi

Kojima

. Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C. World J Gastroenterol 2006; 14: 6786-6791.

40.

Debernardi-Venon

Martini

Biasi

. AT1 receptor antagonist Candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers. J Hepatol 2007; 46: 1026–1033.

41.

Colmenero

Bataller

Sancho-Bru

. Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J Physiol Gastrointest Liver Physiol 2009; 297: G726–G734.

42.

Cholongitas

Vibhakorn

Lodato

. Angiotensin II antagonists in patients with recurrent hepatitis C virus infection after liver transplantation. Liver Int 2010; 30: 334–335.

43.

Hidaka

Nakazawa

Shibuya

. Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: A randomized controlled trial. J Gastroenterol 2011; 46: 1316–1323.

44.

Kim

Cho

Baik

. Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis – a randomized open-label controlled study. Liver Int 2012; 32: 977–987.

45.

Guillaud

Gurram

Puglia

. Angiotensin blockade does not affect fibrosis progression in recurrent hepatitis C after liver transplantation. Transplant Proc 2013; 45: 2331–2336.

46.

Turkay

Yonem

Arici

. Effect of angiotensin-converting enzyme inhibition on experimental hepatic fibrogenesis. Dig Dis Sci 2008; 53: 789–793.

47.

Subeq

Y-M

C-Y

Lin

N-T

. Valsartan decreases TGF-beta 1 production and protects against chlorhexidine digluconate-induced liver peritoneal fibrosis in rats. Cytokine 2011; 53: 223–230.

48.

Tuncer

Ozbek

Ugras

. Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. Exp Toxicol Pathol 2003; 55: 159–166.

49.

Shah

Zheng

Misdraji

. Beneficial effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Hepatology 2007; 46: 703A–704A.

50.

Kim

Cho

Baik

. Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol 2011; 55: 1004–1009.

51.

Kim

Wanless

. The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. J Hepatol 2012; 57: 556–563.

52.

Rastogi

Maiwall

Bihari

. Cirrhosis histology and Laennec staging system correlate with high portal pressure. Histopathology 2013; 62: 731–741.

53.

Wong

Hughes

Trull

. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat 1998; 5: 187–192.

54.

McHutchison

Blatt

de Medina

. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000; 15: 945–951.

55.

Patel

Gordon

Jacobson

. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41: 935–942.

56.

Mehta

Ploutz-Snyder

Nandi

. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2008; 103: 928–936.

57.

Kaneda

Hashimoto

Yatsuji

. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2006; 21: 1459–1465.

58.

Suzuki

Angulo

Lymp

. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005; 25: 779–786.

59.

Pares

Deulofeu

Gimenez

. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996; 24: 1399–1403.

60.

Yamada

Fukuda

Koyama

. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C. J Gastroenterol Hepatol 1996; 11: 646–651.

61.

Crawford

Murphy

Ramm

. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology 2009; 49: 418–425.

62.

Oberti

Pilette

Rifflet

. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepatol 1997; 26: 1363–1371.

63.

Zhou

. A combination of Ang II and carbon tetrachloride accelerates process of hepatic fibrosis. Chin Med J (Engl) 2003; 116: 62–65.

64.

Lebensztejn

Sobaniec-Lotowska

Kaczmarski

. Serum concentration of transforming growth factor (TGF)-beta 1 does not predict advanced liver fibrosis in children with chronic hepatitis B. Hepatogastroenterology 2004; 51: 229–233.

65.

Kim

Baik

Park

. Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model. J Gastroenterol 2008; 43: 889–896.

Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis

Abstract

Background and objective:

Method:

Results:

Conclusions:

Keywords

Introduction

Methods

Search strategy

Inclusion and exclusion criteria

Data extraction and outcome measures

Methodological quality score of the included studies

Data synthesis and statistical analysis

Results

Search

Patient characteristics

Interventions

Fibrosis score of the liver

Fibrosis area of the liver

Fibrosis markers of the liver

Adverse events and withdrawals

Methodological quality of the included studies

Discussion

Footnotes

Declaration of Conflicting Interests

Funding

References